Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Switching from Tirzepatide to Retatrutide: What It Involves
articleAn educational, pharmacokinetics-grounded explainer of what a tirzepatide to retatrutide transition involves: washout timing, the 2mg restart, GI reset, and the investigational reality.
Switch from Semaglutide to Tirzepatide: A Step-by-Step Guide
articleA pharmacokinetics-grounded guide to switching from semaglutide (Ozempic/Wegovy) to tirzepatide (Mounjaro/Zepbound), covering washout timing, dosing on restart, and outcomes.